ArticleHealth science reports2026
Second-Look Ultrasonography for Evaluating BIRADS 3 and 4 Non Mass-Enhancement: A Cross-Sectional Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Breast MRI is a highly sensitive imaging modality for assessing suspected breast lesions; nevertheless, its specificity is poor, ranging from 40% to 80% in various studies. Second-look ultrasound (SLUS) is a tool for the validation of MRI-identified breast abnormalities. This study aimed to assess the role of SLUS as a complementary method for evaluating suspicious non mass-enhancement (NME) on breast MRI. Methods: Fifty patients with 52 non-mass enhancing lesions, classified as BIRADS 3 or 4 on MRI by an expert breast radiologist, were rechecked by SLUS. The relationship between age, breast cancer history, MRI indication, imaging features, and BIRADS classification of the lesions with the sonographic detection rate and pathology findings was analyzed. Results: Out of 52 lesions, 23 were identified on SLUS, 21 patients referred to biopsy. Seven out of 21 biopsies had malignant pathologies. Age less than 40 years, pathological breast discharge, and BIRADS-MRI 4 had a positive relationship with the identification on SLUS. Five of 29 lesions that had no sonographic findings were referred to stereotactic biopsy due to suspicious findings on mammography, and four were malignant on pathology. The only variable that showed a significant relationship with the lesion malignancy was the BIRADS category on MRI. Conclusion: NMEs with BIRADS 4 on MRI were more detectable on SLUS than BIRADS-MRI 3. If detected, ultrasound could not downgrade the BIRADS category of the lesions or exempt them from biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.